



# Vivo Biosciences Inc.

*Accelerating Preclinical Research, Drug Discovery & Therapeutics*

## ANNOUNCEMENT

### **Vivo Biosciences to Present at Drug Discovery Partnerships Meeting in Boston.**

Birmingham, AL – September 28, 2009 – Dr. Raj K. Singh, President and Chief Scientific Officer of Vivo Biosciences, will be presenting a talk at the upcoming Drug Discovery Partnerships: Filling the Pipeline meeting in Boston, MA on Friday, May 30, 2009. Additionally, Vivo Biosciences will have an exhibition booth at the meeting which is organized by Opal Events. The title of Dr. Singh's talk is, "New In Vitro Preclinical Drug Discovery Platform Collaborations: Addressing Needs with 3D Mini-Tumor Bioassay Systems."

#### About Vivo Biosciences, Inc.

Vivo Biosciences, Inc. is an emerging, venture-backed biotechnology company, incorporated in 2004 for the purpose of introducing a novel, human biomatrix, HuBiogel™, to the biological research markets. VBI strives to maximize the functional relevance & predictability of your cell-based assays. We are confident that our unique HuBiogel™ assays will improve drug efficacy/ toxicity endpoints and critical preclinical decisions.

#### About the HuBiogel™ Assay Platform

The 3D HuBiogel™ Assay Platform is a novel in vitro assay platform that recapitulates human cells in a fully human extracellular matrix. These three dimensional systems provide the drug development industry with a cost efficient assay to identify drug efficacy and toxicity. Current systems use animal based or synthetic extracellular matrices which may impact their in vivo predictability.

Vivo Biosciences' Contact: Lee T. Martin, Ph.D.

Source: Vivo Biosciences, Inc.

Vivo Biosciences Website: [www.vivobiotech.com](http://www.vivobiotech.com)